Liberum Capital reissued their buy rating on shares of AstraZeneca plc (LON:AZN) in a research note published on Thursday morning. The firm currently has a GBX 5,500 ($71.65) target price on the biopharmaceutical company’s stock.

Several other equities research analysts have also recently issued reports on AZN. Goldman Sachs Group, Inc. (The) set a GBX 3,900 ($50.81) price objective on shares of AstraZeneca plc and gave the stock a sell rating in a research report on Wednesday, March 29th. Shore Capital reissued a sell rating on shares of AstraZeneca plc in a research report on Sunday, April 2nd. Beaufort Securities reissued a hold rating on shares of AstraZeneca plc in a research report on Monday, April 3rd. BNP Paribas reissued a neutral rating and issued a GBX 5,300 ($69.05) price target on shares of AstraZeneca plc in a research report on Monday, April 3rd. Finally, UBS AG set a GBX 5,150 ($67.09) price target on shares of AstraZeneca plc and gave the company a neutral rating in a research report on Wednesday, April 5th. Three research analysts have rated the stock with a sell rating, ten have given a hold rating and eight have assigned a buy rating to the company. The stock has an average rating of Hold and an average target price of GBX 5,085.05 ($66.25).

ILLEGAL ACTIVITY WARNING: “AstraZeneca plc (AZN) Rating Reiterated by Liberum Capital” was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark laws. The original version of this story can be accessed at https://www.watchlistnews.com/astrazeneca-plc-azn-rating-reiterated-by-liberum-capital/1463891.html.

The firm also recently disclosed a dividend, which will be paid on Monday, September 11th. Stockholders of record on Thursday, August 10th will be given a GBX 68.90 ($0.90) dividend. This represents a dividend yield of 1.35%. The ex-dividend date of this dividend is Thursday, August 10th.

In other AstraZeneca plc news, insider Nazneen Rahman acquired 39 shares of the company’s stock in a transaction dated Thursday, July 27th. The stock was bought at an average price of GBX 4,370 ($56.93) per share, with a total value of £1,704.30 ($2,220.30).

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with Analyst Ratings Network's FREE daily email newsletter.